1. Home
  2. ANL

as 05-13-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Nasdaq

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Founded: 2004 Country:
Cayman Islands
Cayman Islands
Employees: N/A City: N/A
Market Cap: 73.8M IPO Year: 2023
Target Price: $9.00 AVG Volume (30 days): 31.5K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.62 EPS Growth: N/A
52 Week Low/High: $1.26 - $13.92 Next Earning Date: 05-20-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ANL Daily Stock ML Predictions

Share on Social Networks: